Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia

Leuk Res. 1993 May;17(5):441-3. doi: 10.1016/0145-2126(93)90100-y.

Abstract

Recent reports have described clinical benefits of all-trans-retinoic acid (ATRA) therapy for acute promyelocytic leukemia (APL). This paper describes severe hypercalcemia (serum calcium: 18.7 mg/dl) in association with ATRA treatment in a 14 year old girl with APL. Serum parathyroid hormone (PTH) concentrations were normal (0.21 ng/ml), which precludes the possibility of primary hyperparathyroidism or ectopic PTH secretion as a cause of the hypercalcemia. As for the factors which can accelerate mineral resorption, there were no apparent increases in the levels of PTH-related protein (PTH-rP), prostaglandins and vitamin D metabolites. In our in vitro experiment, ATRA did not stimulate the leukemic cells to produce PTH-rP. We speculate that ATRA, like PTH, may increase osteoclastic activity and induce hypercalcemia.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Female
  • Humans
  • Hypercalcemia / chemically induced*
  • Hypercalcemia / complications
  • Leukemia, Promyelocytic, Acute / complications
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Parathyroid Hormone-Related Protein
  • Proteins / metabolism
  • Tretinoin / adverse effects*
  • Tretinoin / therapeutic use

Substances

  • PTHLH protein, human
  • Parathyroid Hormone-Related Protein
  • Proteins
  • Tretinoin